Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.67 |
| ▸ | MMP7 | P09237 | 1/20 | 0.67 |
| ▸ | MMP9 | P14780 | 1/20 | 0.67 |
| ▸ | MMP13 | P45452 | 1/20 | 0.67 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.55 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 1/20 | 0.47 |
| ▸ | FNTB | P49356 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898076 | 0.88 | EZH2 (0.54) | MMP2MMP7MMP9MMP13ADAM17 | |
| SCHEMBL5897966 | 0.86 | ADAM17 (0.55) | MMP2MMP7MMP9MMP13ADAM17 | |
| SCHEMBL5898171 | 0.86 | EZH2 (0.53) | MMP2MMP7MMP9MMP13ADAM17 | |
| SCHEMBL5897928 | 0.86 | ADAM17 (0.58) | MMP2MMP7MMP9MMP13ADAM17 | |
| SCHEMBL5898184 | 0.85 | ADAM17 (0.56) | MMP2MMP7MMP9MMP13ADAM17 | |
| SCHEMBL5898318 | 0.84 | MMP2 (0.48) | MMP2MMP7MMP9MMP13ADAM17 | |
| SCHEMBL5898398 | 0.78 | ADAM17 (0.51) | ADAM17 | |
| SCHEMBL6836251 | 0.77 | ADAM17 (0.57) | MMP7ADAM17 | |
| SCHEMBL5898241 | 0.77 | ADAM17 (0.57) | MMP7ADAM17 | |
| SCHEMBL1757228 | 0.76 | MMP2 (0.54) | MMP2MMP7MMP9MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | LU ZHONGHUI (US) | 2004-08-19 | — | — | US | claimed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | claimed |
| US-6984648-B2 | Cyclic β-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-α | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-01-10 | — | — | US | disclosed |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | LU ZHONGHUI (US) | 2004-08-19 | — | — | US | disclosed |
| US-6743807-B2 | TREATMENT OF RHEUMATOID AND OSTEOARTHRITIS, CORNEAL, EPIDERMAL OR GASTRIC ULCERATION, TUMOR METASTASIS OR INVASION, PERIODONTAL DISEASE AND BONE DISEASE | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-06-01 | — | — | US | disclosed |
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016336-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | MMP2 8/4885MMP7 21/4885MMP9 4/4885 |
| US-20040162426-A1 | Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha | RNPEP, TNF, ANPEP | MMP2 8/4885MMP7 21/4885MMP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.